Treatment of bleeding in severe hemorrhagic pancreatitis with recombinant factor VIIa.
Recombinant factor VIIa (rFVIIa) has been used to treat bleeding complications in patients with hemophilia. It acts at the site of vessel injury, forming a complex with tissue factor to activate the clotting cascade. Recent reports have shown rFVIIa may be a useful hemostatic agent in patients after obstetrical, urologic, trauma, or transplant procedures. We report the first documented case of bleeding from hemorrhage pancreatitis treated with rFVIIa.
Schuster
Rob
R
Department of Surgery, Santa Barbara Cottage Hospital, Santa Barbara, California 93102, USA.
Lee
Sarah J
SJ
Rink
Donald
D
D015942:Factor VIIa / Q000627:therapeutic use*; D006470:Hemorrhage / Q000150:complications / Q000628:therapy*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000150:complications*; D011994:Recombinant Proteins / Q000627:therapeutic use
D006490:Hemostatics; D011994:Recombinant Proteins; D015942:Factor VIIa